Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.

PLoS One 2012 10;7(1):e30123. Epub 2012 Jan 10.

Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.

Objectives: Fatigue is a major cause of disability in primary Sjögren's syndrome (pSS). Fatigue has similarities with sickness behaviour in animals; the latter mediated by pro-inflammatory cytokines, in particular interleukin (IL)-1, acting on neuronal brain cells. We hypothesised that IL-1 inhibition might improve fatigue in pSS patients; thus, we examined the effects and safety of an IL-1 receptor antagonist (anakinra) on fatigue.

Methods: Twenty-six pSS patients participated in a double-blind, placebo-controlled parallel group study. Patients were randomised to receive either anakinra or a placebo for four weeks. Fatigue was evaluated by a fatigue visual analogue scale and the Fatigue Severity Scale. The primary outcome measure was a group-wise comparison of the fatigue scores at week 4, adjusted for baseline values. Secondary outcome measures included evaluation of laboratory results and safety. The proportion of patients in each group who experienced a 50% reduction in fatigue was regarded as a post-hoc outcome. All outcomes were measured at week 4.

Results: There was no significant difference between the groups in fatigue scores at week 4 compared to baseline after treatment with anakinra. However, six out of 12 patients on anakinra versus one out of 13 patients on the placebo reported a 50% reduction in fatigue VAS (p = 0.03). There were two serious adverse events in each group.

Conclusions: This randomised, double-blind, placebo-controlled trial of IL-1 blockade did not find a significant reduction in fatigue in pSS in its primary endpoint. A 50% reduction in fatigue was analysed post-hoc, and significantly more patients on the active drug than on placebo reached this endpoint. Although not supported by the primary endpoint, this may indicate that IL-1 inhibition influences fatigue in patients with pSS.

Trial Registration: ClinicalTrials.gov NCT00683345.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030123PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254637PMC
May 2012
3 Reads

Publication Analysis

Top Keywords

reduction fatigue
16
fatigue
14
50% reduction
12
primary endpoint
8
patients
8
double-blind placebo-controlled
8
fatigue pss
8
fatigue scores
8
il-1 inhibition
8
scores week
8
pss patients
8
primary sjögren's
8
primary
5
il-1
5
randomised receive
4
anakinra placebo
4
receive anakinra
4
fatigue evaluated
4
blockade find
4
visual analogue
4

References

(Supplied by CrossRef)
Sjogren's syndrome.
RI Fox et al.
Lancet 2005
Primary Sjogren's syndrome: a subjective description of the disease.
K Bjerrum et al.
Clin Exp Rheumatol 1990
Primary Sjogren's syndrome: too dry and too tired.
WF Ng et al.
Rheumatology (Oxford) 2010
Cytokine-induced sickness behavior: where do we stand?
R Dantzer et al.
Brain Behav Immun 2001

Similar Publications